<DOC>
	<DOCNO>NCT00508404</DOCNO>
	<brief_summary>To estimate effect KRAS mutation status ( Wild-type versus Mutant ) objective response rate measure efficacy patient treat panitumumab combination chemotherapy regimen irinotecan , 5-fluorouracil , leucovorin ( FOLFIRI ) first-line therapy metastatic colorectal cancer ( mCRC ) .</brief_summary>
	<brief_title>Panitumumab Plus FOLFIRI First-line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosed histologically cytologicallyconfirmed metastatic adenocarcinoma colon and/or rectum . Measurable disease accord modified RECIST guideline . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Paraffinembedded tissue unstained tumour slide primary metastatic tumour available central lab analysis . Adequate haematologic , renal , hepatic metabolic function . Central nervous system metastasis . Prior systemic therapy treatment metastatic colorectal carcinoma exception adjuvant fluoropyrimidinebased chemotherapy give least six month prior initiate study treatment . Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy ( e.g . cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( e.g . erlotinib ) . Prior radiotherapy within 14 day prior screen , sign early radiological toxicity abate . Significant cardiovascular disease include unstable angina myocardial infarction within six month initiate study treatment history ventricular arrhythmia . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest compute tomography ( CT scan . Active inflammatory bowel disease bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) . History Gilbert 's syndrome dihydropyrimidine deficiency . Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection . Any investigational agent within 30 day initiation study treatment . Must major surgical procedure within 28 day prior initiation study treatment . Subject pregnant breastfeeding . Woman man childbearing potential consenting use adequate contraceptive precaution course study six month last study drug administration woman , one month men . Other protocol specify criterion specific detail may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>